Early clinical research
Personalized mRNA neoantigen vaccine — resected PDAC (phase I)
Phase 1 Clinical Trial of Personalized Neoantigen Tumor Vaccines and PD-L1 Blockade in Patients With Surgically Resected Pancreatic Cancer
- Phase
- Phase I
- Recruitment
- Active, not recruiting
- Results maturity
- Interim analysis
- Publication
- Peer-reviewed
- Regulatory approval
- No regulatory approval
- NCT
- NCT04161755
- Registry checked
- 2026-10-29
- Editorial update
- 2026-10-29
Not a treatment recommendation. Experimental or ongoing research does not by itself replace standard care.
For patients
What is being studied? Personalized mRNA vaccines after surgery are being studied to strengthen immunity and possibly delay recurrence in pancreatic cancer. This is early-phase research.
Why promising? Early signal linking personalized mRNA vaccine immunogenicity and durable T-cell responses in PDAC.
What is not proven? Randomized RFS/OS superiority; standard adjuvant role in a broad population.
Is this standard care today? This listing alone does not replace standard care; approval and guideline context require clinician judgment.
For clinicians
n=29 (16 vaccinated). Nature 2025 longer follow-up: longer RFS in responders (exploratory). Primary endpoint is safety.
Cancer / population: Pancreas — Rezeke edilebilir PDAC
Intervention: Cerrahi → atezolizumab → autogene cevumeran → mFOLFIRINOX
Primary endpoint: Güvenlik (ilaç ilişkili toksisite)
Limitations: Tek kollu, küçük n; yanıt–RFS ilişkisi nedensellik kanıtı değildir.